UNDERWRITING
Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus supplement, Goldman Sachs & Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, UBS Securities LLC, SunTrust Robinson Humphrey, Inc., BTIG, LLC and CJS Securities, Inc have severally agreed to purchase, and we have agreed to sell to them, severally, the number of ordinary shares indicated below:
| | | | |
Name | | Number of Shares | |
Goldman Sachs & Co. LLC | | | 4,321,015 | |
Barclays Capital Inc. | | | 2,871,739 | |
Citigroup Global Markets Inc. | | | 2,871,739 | |
Credit Suisse Securities (USA) LLC | | | 2,871,739 | |
UBS Securities LLC | | | 2,871,739 | |
SunTrust Robinson Humphrey, Inc. | | | 750,000 | |
BTIG, LLC | | | 416,667 | |
CJS Securities, Inc | | | 416,667 | |
| | | | |
Total: | | | 17,391,305 | |
Goldman Sachs & Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, UBS Securities LLC, SunTrust Robinson Humphrey, Inc., BTIG, LLC and CJS Securities, Inc are collectively referred to as the “underwriters.” The underwriters are offering the ordinary shares subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the ordinary shares offered by this prospectus supplement are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the ordinary shares offered by this prospectus supplement if any such shares are taken.
The underwriters initially propose to offer part of the ordinary shares of directly to the public at the offering price listed on the cover page of this prospectus supplement and part to certain dealers at a price that represents a concession not in excess of $0.36 per share under the public offering price. After the initial offering of the ordinary shares, the offering price and other selling terms may from time to time be varied by the underwriters.
The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part.
The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional ordinary shares.
| | | | | | | | | | | | |
| | Per Share | | | Without Option | | | With Option | |
Public offering price | | $ | 20.00 | | | $ | 347,826,100 | | | | 400,000,000 | |
Underwriting discounts and commissions | | $ | 0.60 | | | $ | 10,434,783 | | | | 12,000,000 | |
Proceeds, before expenses, to us | | $ | 19.40 | | | $ | 337,391,317 | | | | 388,000,000 | |
The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $600,000. We have agreed to reimburse the underwriters up to $35,000 for certain expenses incurred in connection with this offering.
We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus supplement, to purchase up to 2,608,695 additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter’s initial amount reflected in the above table.
Our ordinary shares are listed on the New York Stock Exchange under the trading symbol “NOMD”.
We and certain of our executive officers and directors have entered intolock-up agreements with the underwriters or otherwise agreed, subject to certain exceptions, that we and they will not, directly or indirectly, offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale, or otherwise dispose of or hedge any of our shares of common stock, any options or warrants to purchase shares of our common stock, or any securities
S-22